EYE
National Vision Holdings, Inc.
EYE has the edge over LCID overall, supported by stronger valuation and lower modeled downside.
LCID
Lucid Group, Inc.
LCID's outlook is improving, though it still trails on the overall score.
EYE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Healthy |
EYE's profitability and balance sheet are currently healthy, and its revenue is stable, but its cash flow is under pressure.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
EYE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $18.57 | — |
| Current | 23x | $18.57 | — |
| Cheap | 28x | $22.52 | +21% |
| Fair | 50x | $40.68 | +119% |
| Expensive | 103x | $83.20 | +348% |
Historical ranges are pointers, not guarantees.
EYE's PE is in its cheap range at 23x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
EYE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect EYE's earnings to grow and its profitability to improve, with its revenue holding steady.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
EYE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.16 | +44% |
| Q3 2026 | $0.81 | +$0.84 |
| Q2 2026 | $0.61 | +$0.79 |
| Q1 2026 | $0.57 | +$0.90 |
| Q4 2025 | $0.37 | +$0.73 |
| Q3 2025 | -$0.03 | +$0.16 |
| Q2 2025 | -$0.18 | +$0.84 |
| Q1 2025 | -$0.33 | +$0.58 |
| Q4 2024 | -$0.36 | +$0.48 |
EYE has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
EYE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $510.5M | +4.8% |
| Q2 2026 | $498.8M | +2.5% |
| Q1 2026 | $543.9M | +6.6% |
| Q4 2025 | $503.4M | +15% |
| Q3 2025 | $487.3M | +7.9% |
| Q2 2025 | $486.4M | +7.7% |
| Q1 2025 | $510.3M | -5.9% |
| Q4 2024 | $437.3M | -14% |
EYE's revenue has grown year over year for six quarters in a row: $511M last quarter, up 4.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.1% | +4.1 points |
| Q2 2026 | 4.3% | +0.9 points |
| Q1 2026 | 8.3% | +3.2 points |
| Q4 2025 | 1.3% | +7.2 points |
| Q3 2025 | 2% | +3.9 points |
| Q2 2025 | 3.4% | +3.3 points |
| Q1 2025 | 5.1% | +0.6 points |
| Q4 2024 | -5.8% | -3.2 points |
EYE has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over EYE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
EYE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $49.3M | +63% |
| Q2 2026 | -$14.1M | -133% |
| Q1 2026 | $44.1M | +267% |
| Q4 2025 | -$11.2M | -$9.5M |
| Q3 2025 | $30.3M | +647% |
| Q2 2025 | $42.4M | +33% |
| Q1 2025 | $12M | +202% |
| Q4 2024 | -$1.7M | +$11.3M |
EYE has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
EYE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -533K shares |
| 1 year | -1.4% | -1.1M shares |
| 3 years | +2.4% | +1.9M shares |
| 5 years | -17% | -16.4M shares |
| Available history | -2.1% | -1.7M shares |
EYE has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $21.4M |
| Q2 2026 | $20.1M |
| Q1 2026 | $10.5M |
| Q4 2025 | $650,000 |
| Q3 2025 | $876,000 |
| Q2 2025 | $55,000 |
| Q1 2025 | $1.6M |
| Q4 2024 | $273,000 |
EYE spent $53M buying back its own shares over the past year, more than ten times what it spent the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
EYE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.9x | Very low |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 1.0x | Very low |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.2x | Elevated |
EYE's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EYE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.6 | Neutral |
| Stochastic | 33.1 | Neutral |
EYE's weekly RSI is 49 (neutral) and its Stochastic is 33 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
EYE PE vs Consumer Cyclical Sector
| Metric | EYE | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 18x | 27% above |
| PE % | 7 | 47 | 40 pts below |
EYE is trading at 23x earnings, a 27% premium to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
EYE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.4 | 7% above |
| 20 week MA | $18.4 | 0.7% above |
| 50 week MA | $22.0 | 16% below |
| 100 week MA | $20.5 | 9.5% below |
| 200 week MA | $19.7 | 5.6% below |
EYE has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
EYE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.1 | $47.3 | +43% |
| 2021 | $47.3 | $47.8 | +1.1% |
| 2022 | $47.8 | $38.7 | -19% |
| 2023 | $38.7 | $20.9 | -46% |
| 2024 | $20.9 | $10.6 | -49% |
| 2025 | $10.6 | $28.0 | +165% |
| 2026 YTD | $28.0 | $18.6 | -34% |
EYE has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.